CALGARY, AB--(Marketwired - November 05, 2014) - Encana Corporation (TSX: ECA) (NYSE: ECA) will release its third quarter 2014 results on Wednesday, November 12, 2014.
MSCI Inc. (NYSE:MSCI) announced today the pricing of a private offering
of $800 million aggregate amount of 5.250% senior notes due November 15,
2024 at an issue price of 100% to yield 5.250% (the “Offering”). The
Offering is expected to settle on November 20, 2014, subject to
customary closing conditions.
Kindred Healthcare, Inc. (“Kindred” or the “Company”) (NYSE:KND) today
announced that upon closing of the Company’s previously announced
acquisition of Gentiva Health Services, Inc. (“Gentiva”) (NASDAQ:GTIV),
which is expected in the first quarter of 2015, David Causby will become
the President of the combined Kindred at Home business.
TravelCenters of America LLC (NYSE: TA) today announced that it plans to
issue a press release containing its third quarter 2014 financial
results before the NYSE opens for trading on Monday, November 10, 2014.
First American Financial Corporation (NYSE: FAF), a leading
provider of title insurance, settlement services and risk solutions for
real estate transactions, today announced the pricing of a public
offering of $300.0 million of its 4.6 percent senior notes due 2024.
Kimball International, Inc. (NASDAQ: KBAL), today announced the planned
consolidation of its metal fabrication production from its operation
located in Post Falls, Idaho, into existing production facilities in
Sign-up for Kimball International Announces Plan to Consolidate Manufacturing Capacity to Be More Responsive to Markets and Reduce Cost Structure; Idaho Manufacturing To Be Transferred To Indiana Facilities investment picks
-3Q distribution increased 5% versus 2Q, 16.4% versus 3Q 2013 levels -Gallons sold increased 17% versus 3Q 2013 volumes -Equity and bank financings significantly expand capacity for growth
-Pending and completed acquisitions expected to significantly increase Partnership's EBITDA(1) and distributable cash flow(1) Conference Call Scheduled for 10:00 a.m. ET (9:00 a.m. CT) on November 6 HOUSTON , Nov.
BUNAVAIL™ (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence Positive top-line results from second Phase 3 BEMA Buprenorphine clinical trial in chronic pain; recent pre-NDA meeting confirmed NDA submission on track for year-end or early 2015
Positive interim analysis completed in Phase 3 trial of Clonidine Topical Gel for painful diabetic neuropathy; Top-line results anticipated by end of first quarter 2015 Agreement signed to develop and commercialize long-acting, injectable, microparticle formulation of buprenorphine for opioid dependence and pain to compliment current portfolio RALEIGH, N.C. , Nov.
Third Quarter 2014 Results Revenue was $305.9 Million ($305.8 Million Non-GAAP); Operating Income was $21.3 Million, 7.0 Percent of Revenue (7.0 Percent Non-GAAP);
Fully Diluted EPS were 27 Cents (31 Cents Non-GAAP); Signs Record $125 Million in New Business ($340 Million Year-to-date) Updated Full-year 2014 Revenue and Operating Margin Guidance DENVER , Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.